The latest price target for Taysha Gene Therapies (NASDAQ:TSHA) was reported by Canaccord Genuity on November 15, 2024. The analyst firm set a price target for $8.00 expecting TSHA to rise to within 12 months (a possible 279.15% upside). 36 analyst firms have reported ratings in the last year.

The latest analyst rating for Taysha Gene Therapies (NASDAQ:TSHA) was provided by Canaccord Genuity, and Taysha Gene Therapies maintained their buy rating.

There is no last upgrade for Taysha Gene Therapies

The last downgrade for Taysha Gene Therapies Inc happened on February 2, 2023 when BTIG changed their price target from N/A to N/A for Taysha Gene Therapies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taysha Gene Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taysha Gene Therapies was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Taysha Gene Therapies (TSHA) rating was a maintained with a price target of $6.00 to $8.00. The current price Taysha Gene Therapies (TSHA) is trading at is $2.11, which is out of the analyst’s predicted range.